This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.
Assertio (ASRT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.
Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ASRT) Outperforming Other Medical Stocks This Year?
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $1.14, marking a -1.72% move from the previous day.
ASRT or PCRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $1.07, moving -0.93% from the previous trading session.
Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
by Zacks Equity Research
Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA
by Zacks Equity Research
The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
by Zacks Equity Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
ASRT vs. PCRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
by Zacks Equity Research
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales
by Zacks Equity Research
PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.
Assertio (ASRT) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 4.35% and -6.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Top Ranked Value Stocks to Buy for September 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, September 9th
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Assertio Therapeutics Enters Oversold Territory
by Zacks Equity Research
Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
ASRT vs. PCRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. PCRX: Which Stock Is the Better Value Option?
Assertio (ASRT) Q2 Earnings Beat Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT or AMRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. AMRX: Which Stock Is the Better Value Option?